THU0226 ASAS Partial Remission Ratio of as and Axial Spondyloarthritis Patients During Anti-TNF Treatments: HUR-BIO Real Life Results. (9th June 2015)

• Record Type: Journal Article
• Authors: Kalyoncu, U.; Kilic, L.; Erden, A.; Seyhoglu, E.; Kilickap, S.; Sener, Y.Z.; Aktas, B.Y.; Guven, D.; Karadag, O.; Akdogan, A.; Bilgen, S.A.; Ertenli, I.; Kiraz, S.
• Is Part Of: Annals of the rheumatic diseases. Volume 74(2015)Supplement 2
• Page Start: 278
• Page End: 278
• Publication Date: 2015-06-09
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2015-eular.4235
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: ASAS partial remission is relevant treatment target for ankylosing spondylitis (AS) and axial spondyloarthritis (AxSpA) patients. Objectives: Objective of this study was to assess ASAS partial remission ratio during anti-TNF treatment in real life experience. Second objective was to assess related factors of ASAS partial remission at both AS and AxSpA. Methods: HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single center biological registry since 2005. HUR-BIO includes patients with AS and AxSpA under anti-TNF drugs. HUR-BIO biological dataset included demographic data, education level, co-morbidities, smoking status. After september 2012, outcome measures of ASAS were recorded regularly every six months or during switched of anti-TNF. Outcome measures of HUR-BIO include BASDAI, BASDAI 2, 5 and 6. questions, BASFI, VAS global, VAS pain, VAS fatique, ESR and CRP. ASAS partial remission was defined as less than 20/100 mm of BASFI, back pain, morning stiffness and VAS global. ASAS partial remission was calculated according to last control visit of patients. Results: There were 874 patients (747 AS and 127 AxSpA) in HUR-BIO dataset. Among 716 of 874 (81.9%) patients [602 (84.1%) and AxSPA 115 (15.9%)] had at least one control visit during last 2 years. Overall, 452 of those 716 (63.1%) patients were male. Mean age (41.3±11.3 vs 35.5±9.7, p<0.001), mean disease duration (9.8±7.3 vs 4.3±2.9, p<0.001), and mean symptom duration (14.3±8.8 vs 7.8±6.6, p<0.001) were higher at AS than AxSpA patients. Initial anti-TNF drugs were etanercept 249 (34.8%), adalimumab 197 (27.5%), infliximab 208 (29.1%) and golimumab 62 (8.6%). Anti-TNF switch was found 207 (28.9%) of patients. ASAS partial remission was found at 205 (28.6%) patients (29.7% vs 22.8%, p=0.13, for AS and AxSpA, respectively). Results of univariate analysis related with ASAS remission was shown at table 1 . In logistic regression analysis, positive HLA-B27 OR 3.76 (CI 95% 1.34-10.56, p=0.012), baseline CRP upper than normal limit OR 4.65 (CI 95%, 1.67-12.95, p=0.003) and disease duration less than 5 years OR 0.32 (95%CI 0.14-0.77, P=0.01) were related with ASAS partial remission. Conclusions: At real life experience, ASAS partial remission was reached only almost 29% of AS and 23% of AxSpA patients. We should keep in mind that, almost 20% of patients were not followed in HUR-BIO and analysis was performed only patients with continue anti-TNF treatments. Patients with HLA B27 positive, high baseline CRP and disease duration less than 5 years were candidate for remission. Disclosure of Interest: None declared